ICIs have shown minimal efficacy in EGFR-mutant NSCLC across various trials, with low overall response rates (ORR), progression-free survival (PFS), and no significant survival benefit compared to chemotherapy [92,93,127,128]. Here, EGFR is linked to non-small cell lung carcinoma.